Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Methods. MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis. Results. 577 cases of NAFLD/NASH in ten randomized controlled trials (RCTs) were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFA treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL. Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.

• Publication year

  2016

• Venue

  Gastroenterology Research and Practice

• Publication date

  2016-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2016/1459790PMID 27651787PMCID 5019889
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".

  2017cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

  2016cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

  2016cited by this paper
• Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

  2015cited by this paper
• Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis

  2015cited by this paper
• Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

  2015cited by this paper
• By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice

  2015cited by this paper
• Current efforts and trends in the treatment of NASH.

  2015cited by this paper
• Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.

  2015cited by this paper
• Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial–mesenchymal transition: Partial mediation by the transcription factor NFAT1

  2015cited by this paper
• Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

  2014cited by this paper
• Hydrogen sulfide, a potential novel drug, attenuates concanavalin a-induced hepatitis

  2014cited by this paper
• Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets

  2014cited by this paper
• Dietary Fucoxanthin Increases Metabolic Rate and Upregulated mRNA Expressions of the PGC-1alpha Network, Mitochondrial Biogenesis and Fusion Genes in White Adipose Tissues of Mice

  2014cited by this paper
• No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

  2014cited by this paper
• Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis

  2014cited by this paper
• The role of medications for the management of patients with NAFLD.

  2014cited by this paper
• Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis

  2013cited by this paper
• Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications

  2013cited by this paper
• Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

  2013cited by this paper
• Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

  2012cited by this paper
• Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

  2012influential reference
• The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

  2012cited by this paper
• The epidemiology, pathogenesis and histopathology of fatty liver disease

  2012cited by this paper
• Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?

  2012cited by this paper
• The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.

  2012cited by this paper
• N-3 PUFA Supplementation Triggers PPAR-α Activation and PPAR-α/NF-κB Interaction: Anti-Inflammatory Implications in Liver Ischemia-Reperfusion Injury

  2011cited by this paper
• Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet.

  2011cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study

  2010cited by this paper
• Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

  2010cited by this paper
• Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

  2010cited by this paper
• Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.

  2009cited by this paper
• Nonalcoholic fatty liver disease and its association with cardiovascular disease.

  2009cited by this paper
• Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.

  2009cited by this paper
• Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans

  2008cited by this paper
• Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.

  2008cited by this paper
• Therapeutic efficacy of ω-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease

  2008cited by this paper
• Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

  2008cited by this paper
• The epidemiology of nonalcoholic fatty liver disease: a global perspective.

  2008cited by this paper
• Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

  2008cited by this paper
• Dietary habits and nutrient intake in non-alcoholic steatohepatitis.

  2007cited by this paper
• Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease.

  2007cited by this paper
• Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study

  2006cited by this paper
• Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review.

  2006cited by this paper
• How different is the dietary pattern in non-alcoholic steatohepatitis patients?

  2006cited by this paper
• Omega-3 Fatty Acid Supplementation Prevents Hepatic Steatosis in a Murine Model of Nonalcoholic Fatty Liver Disease

  2005cited by this paper
• Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor.

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease.

  2004cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper
• European Association for the study of diabetes

  1969cited by this paper

• The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status

  2026cites this paper
• The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials

  2026cites this paper
• Nutrition and Liver Disease

  2025cites this paper
• Body composition mediates the association between fatty acids and NAFLD risk: a prospective cohort study

  2025cites this paper
• Efficacy of non-pharmacological treatments in pediatric MASLD: a review of the literature

  2025cites this paper
• Interrelationship between alcohol consumption, overnutrition, and pharmacotherapy for liver steatosis: Considerations and proposals.

  2025cites this paper
• Interaction between dietary omega‐3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials

  2025cites this paper
• Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials.

  2025cites this paper
• Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver

  2025cites this paper
• Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies

  2025influential citation
• Omega-3 Fatty Acids, Furan Fatty Acids, and Hydroxy Fatty Acid Esters: Dietary Bioactive Lipids with Potential Benefits for MAFLD and Liver Health

  2025cites this paper
• Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis

  2025cites this paper
• Effects of seal oil supplementation on lipid profile biomarkers: A systematic review and meta-analysis of randomized controlled trials.

  2025cites this paper
• Efficacy of omega-3 fatty acids as a functional food: a multifaceted approach to health reinforcement.

  2025cites this paper
• Management of Steatosis in Living Donors: Where Do We Stand?

  2024cites this paper
• The effects of saturated and unsaturated fatty acids on MASLD: a Mendelian randomization analysis and in vivo experiment

  2024cites this paper
• Cicer arietinum phytosome ameliorates hepatosteatosis via downregulation of fatty acid synthase and stearoyl-CoA desaturase 1 in rats

  2024cites this paper
• From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status

  2024cites this paper
• Oral intake of the microalgae Nannochloropsis oceanica, Chlorella vulgaris, or Phaeodactylum tricornutum improves metabolic conditions in hypercaloric-fed mice

  2024cites this paper
• Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Impact of Flaxseed Supplementation on Lipid Profile and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  2024cites this paper
• Natural products and dietary interventions on liver enzymes: an umbrella review and evidence map

  2024cites this paper
• NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials

  2023cites this paper
• Adherence to a Traditional Mexican Diet Is Associated with Lower Hepatic Steatosis in US-Born Hispanics of Mexican Descent with Overweight or Obesity

  2023cites this paper
• Effect of Vitamins A, E, D3 Supplemented with Omega3 and Vitamins A, E, D3 (without Omega -3) on Biochemical Blood Parameters of Females Awassi Lamb

  2023cites this paper
• Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

  2023cites this paper
• Fatty acid composition but not quantity is an important indicator of non-alcoholic fatty liver disease: a systematic review

  2023cites this paper
• Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk.

  2023cites this paper
• Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2023cites this paper
• Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases

  2023cites this paper
• Associations of fatty acids composition and estimated desaturase activities in erythrocyte phospholipids with biochemical and clinical indicators of cardiometabolic risk in non-diabetic Serbian women: the role of level of adiposity

  2023cites this paper
• Fatty liver index relationship with biomarkers and lifestyle: result from RaNCD cohort study

  2023cites this paper
• The association between dietary diabetic risk reduction score with anthropometric and body composition variables in overweight and obese women: a cross-sectional study

  2023cites this paper
• Ewe early gestation supplementation with eicosapentaenoic and docosahexaenoic acids affects the liver, muscle, and adipose tissue fatty acid profile and liver mRNA expression in the offspring.

  2023cites this paper
• The effects of camelina sativa oil and high-intensity interval training on liver function and metabolic outcomes in male type 2 diabetic rats

  2023cites this paper
• Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease

  2023cites this paper
• Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease

  2023cites this paper
• Omega‐3 polyunsaturated fatty acids in the treatment of non‐alcoholic fatty liver disease: An umbrella systematic review and meta‐analysis

  2023cites this paper
• The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials.

  2022cites this paper
• Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden.

  2022cites this paper
• Partial Replacement of Dietary Fat with Krill Oil or Coconut Oil Alleviates Dyslipidemia by Partly Modulating Lipid Metabolism in Lipopolysaccharide-Injected Rats on a High-Fat Diet

  2022cites this paper
• Dietary linoleic acid and the ratio of unsaturated to saturated fatty acids are inversely associated with significant liver fibrosis risk: A nationwide survey

  2022cites this paper
• Dietary fatty acids and risk of non-alcoholic steatohepatitis: A national study in the United States

  2022cites this paper
• Taurine Attenuates Oxidized Fish Oil-Induced Oxidative Stress and Lipid Metabolism Disorder in Mice

  2022influential citation
• Mitochondria-targeted anti-oxidant AntiOxCIN4 improved liver steatosis in Western diet-fed mice by preventing lipid accumulation due to upregulation of fatty acid oxidation, quality control mechanism and antioxidant defense systems

  2022cites this paper
• Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials

  2022cites this paper
• Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Preventive role of Sapindus species in different neurological and metabolic disorders

  2022cites this paper
• Glycated albumin as a biomarker for diagnosis of diabetes mellitus: A systematic review and meta-analysis

  2021cites this paper
• Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis

  2021cites this paper
• Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease

  2021cites this paper
• Changes in carcass traits, meat quality, muscle fiber characteristics, and liver function of finishing pigs fed high level of fish oil

  2021cites this paper
• Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome.

  2021cites this paper
• Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial

  2021influential citation
• Therapeutic Potential of Pro-Resolving Mediators in Diabetic Kidney Disease.

  2021cites this paper
• Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids

  2021cites this paper
• Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis

  2021cites this paper
• Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives

  2021cites this paper
• Evaluation of efficacy and tolerability of hepameg (probiotics + eicosapentaenoic acid + docosahexaenoic acid + vitamin E) in the management of non-alcoholic fatty liver disease

  2021cites this paper
• Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD

  2020cites this paper
• The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement

  2020cites this paper
• Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View

  2020cites this paper
• Liver disease

  2020cites this paper
• Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult

  2020cites this paper
• NAFLD and cardiovascular diseases: a clinical review

  2020cites this paper
• Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

  2020influential citation
• DHA reduces hypothalamic inflammation and improves central leptin signaling in mice.

  2020cites this paper
• Die nicht-alkoholische Fettlebererkrankung bei Kindern und Jugendlichen – ein Update

  2020cites this paper
• A Prudent dietary pattern is inversely associated with liver fat content among multi‐ethnic youth

  2020cites this paper
• Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease

  2020cites this paper
• Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease

  2020cites this paper
• Ketogenic, Hypocaloric Diet Improves Nonalcoholic Steatohepatitis

  2020cites this paper
• Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.

  2019cites this paper
• Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation

  2019cites this paper
• A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease

  2019cites this paper
• Erythrocyte membrane n-3 polyunsaturated fatty acids are inversely associated with the presence and progression of nonalcoholic fatty liver disease in Chinese adults: a prospective study

  2019cites this paper
• A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)

  2019cites this paper
• Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered

  2019cites this paper
• Is the Fatty Acids Profile in Blood a Good Predictor of Liver Changes? Correlation of Fatty Acids Profile with Fatty Acids Content in the Liver

  2019cites this paper
• Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs

  2019cites this paper
• The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease

  2019influential citation
• Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review

  2019cites this paper
• Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation

  2019cites this paper
• Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

  2018cites this paper
• Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

  2018cites this paper
• Обзор Лечение неалкогольной жировой болезни печени диетой и физической активностью

  2018cites this paper
• Ernährungstherapie der nichtalkoholischen Fettleber

  2018cites this paper
• Lösungen statt Leitlinien

  2018influential citation
• Effects of Consumption of Various Fatty Acids on Serum HDL-Cholesterol Levels

  2018cites this paper
• Role of Borage Seed Oil and Fish Oil with or without Turmeric and Alpha- Tocopherol in Prevention of Cardiovascular Disease and Fatty Liver in Rats.

  2018cites this paper
• Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis

  2018cites this paper
• Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study.

  2018cites this paper
• A meta-analysis of randomized controlled trials of Yiyiren Decoction in the treatment of rheumatoid arthritis

  2018influential citation
• Microbiota, Obesity and NAFLD.

  2018cites this paper
• Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease

  2018cites this paper
• The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

  2018cites this paper
• Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease

  2018cites this paper
• Euodia daniellii Hemsl. (Bee-Bee Tree) Oil Attenuates Palmitate-Induced Lipid Accumulation and Apoptosis in Hepatocytes

  2018cites this paper